• Consensus Rating: Hold
  • Consensus Price Target: $1,787.50
  • Forecasted Upside: 4,349.84 %
  • Number of Analysts: 9
  • Breakdown:
  • 1 Sell Ratings
  • 7 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
▼ -0.14 (-0.35%)

This chart shows the closing price for GSK by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New GSK Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for GSK and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for GSK

Analyst Price Target is $1,787.50
▲ +4,349.84% Upside Potential
This price target is based on 9 analysts offering 12 month price targets for GSK in the last 3 months. The average price target is $1,787.50, with a high forecast of $1,900.00 and a low forecast of $1,600.00. The average price target represents a 4,349.84% upside from the last price of $40.17.

This chart shows the closing price for GSK for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 9 contributing investment analysts is to hold stock in GSK. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 6 hold ratings
  • 2 sell ratings
  • 0 strong buy ratings
  • 4 buy ratings
  • 7 hold ratings
  • 2 sell ratings
  • 0 strong buy ratings
  • 5 buy ratings
  • 7 hold ratings
  • 2 sell ratings
  • 0 strong buy ratings
  • 2 buy ratings
  • 7 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 2 buy ratings
  • 6 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 2 buy ratings
  • 7 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 1 buy ratings
  • 6 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 1 buy ratings
  • 7 hold ratings
  • 1 sell ratings

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 7 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/5/2022Morgan StanleyReiterated RatingEqual WeightLow
7/21/2022CitigroupReiterated RatingNeutralLow
7/20/2022UBS GroupLower Price TargetGBX 1,876 ➝ GBX 1,850Low
7/15/2022Credit Suisse GroupBoost Price TargetGBX 1,400 ➝ GBX 1,600Low
4/29/2022BarclaysBoost Price TargetGBX 1,775 ➝ GBX 1,800Low
4/28/2022JPMorgan Chase & Co.Boost Price TargetGBX 1,740 ➝ GBX 1,900Low
4/14/2022BarclaysBoost Price TargetGBX 1,675 ➝ GBX 1,775Low
2/28/2022Stifel NicolausInitiated CoverageHoldLow
2/11/2022DZ BankDowngradeBuy ➝ HoldLow
11/24/2021Berenberg BankReiterated RatingBuyMedium
11/8/2021UBS GroupReiterated RatingNeutralLow
11/5/2021BarclaysUpgradeUnderweight ➝ Equal WeightMedium
11/3/2021Morgan StanleyReiterated RatingEqual WeightLow
11/1/2021JPMorgan Chase & Co.Reiterated RatingNeutralLow
10/28/2021BarclaysReiterated RatingUnderweightLow
10/18/2021Berenberg BankReiterated RatingBuyLow
10/7/2021Morgan StanleyReiterated RatingEqual WeightLow
9/20/2021UBS GroupReiterated RatingNeutralLow
8/26/2021UBS GroupReiterated RatingNeutralLow
8/20/2021JPMorgan Chase & Co.Reiterated RatingNeutralLow
8/19/2021Berenberg BankReiterated RatingBuyLow
8/3/2021UBS GroupReiterated RatingNeutralLow
7/19/2021BarclaysReiterated RatingUnderweightMedium
7/6/2021Morgan StanleyReiterated RatingEqual WeightLow
7/1/2021UBS GroupReiterated RatingNeutralLow
6/24/2021Credit Suisse GroupReiterated RatingUnderperformLow
6/23/2021Deutsche Bank AktiengesellschaftUpgradeSell ➝ HoldLow
6/11/2021Deutsche Bank AktiengesellschaftReiterated RatingSellLow
6/2/2021Baader BankReiterated RatingBuyLow
5/11/2021UBS GroupReiterated RatingNeutralLow
4/30/2021Deutsche Bank AktiengesellschaftReiterated RatingSellLow
4/20/2021Morgan StanleyReiterated RatingEqual WeightLow
4/20/2021UBS GroupReiterated RatingNeutralLow
3/29/2021SVB LeerinkReiterated RatingOutperform ➝ Market PerformN/A
3/23/2021SVB LeerinkDowngradeOutperform ➝ Market PerformLow
2/12/2021Morgan StanleyReiterated RatingEqual WeightLow
2/11/2021Berenberg BankReiterated RatingBuyLow
2/9/2021JPMorgan Chase & Co.Reiterated RatingNeutralLow
2/8/2021UBS GroupReiterated RatingNeutralLow
2/5/2021BarclaysReiterated RatingUnderweightLow
2/3/2021Deutsche Bank AktiengesellschaftDowngradeHold ➝ SellLow
1/20/2021UBS GroupReiterated RatingNeutralLow
1/20/2021Credit Suisse GroupDowngradeNeutral ➝ UnderperformLow
1/15/2021Deutsche Bank AktiengesellschaftInitiated CoverageHoldLow
12/16/2020DZ BankReiterated RatingBuyLow
12/8/2020JPMorgan Chase & Co.Reiterated RatingNeutralLow
12/3/2020UBS GroupDowngradeBuy ➝ NeutralLow
11/13/2020Morgan StanleyUpgradeUnderweight ➝ Equal WeightLow
11/2/2020Liberum CapitalUpgradeHold ➝ BuyLow
10/30/2020BarclaysReiterated RatingUnderweightLow
10/21/2020JPMorgan Chase & Co.Reiterated RatingNeutralLow
10/12/2020UBS GroupReiterated RatingBuyLow
10/9/2020Morgan StanleyReiterated RatingUnderweightLow
10/5/2020Credit Suisse GroupReiterated RatingNeutralLow
9/29/2020Berenberg BankInitiated CoverageBuyLow
9/23/2020Oddo BhfUpgradeNeutral ➝ BuyMedium
9/18/2020Societe GeneraleReiterated RatingBuyLow
9/8/2020JPMorgan Chase & Co.Reiterated RatingNeutralMedium
9/1/2020Morgan StanleyReiterated RatingUnderweightMedium
8/12/2020UBS GroupReiterated RatingBuyLow
5/14/2020UBS GroupReiterated RatingBuyLow
5/5/2020JPMorgan Chase & Co.Reiterated RatingNeutralLow
4/30/2020BarclaysReiterated RatingUnderweightLow
2/12/2020Shore CapitalDowngradeHold ➝ SellLow
1/16/2020BarclaysDowngradeEqual Weight ➝ UnderweightLow
12/2/2019SVB LeerinkInitiated CoverageOutperformLow
11/27/2019UBS GroupUpgradeNeutral ➝ BuyN/A
11/21/2019UBS GroupUpgradeNeutral ➝ BuyLow
10/16/2019New Street ResearchUpgradeReduce ➝ HoldLow
10/11/2019Cantor FitzgeraldUpgradeHold ➝ BuyMedium
9/3/2019Societe GeneraleUpgradeSell ➝ BuyLow
8/29/2019Jefferies Financial GroupReiterated RatingBuyLow
8/13/2019JPMorgan Chase & Co.Reiterated RatingNeutral ➝ NeutralLow
6/17/2019Morgan StanleyReiterated RatingUnderweight ➝ UnderweightLow
6/10/2019CowenReiterated RatingHold$45.00Low
3/8/2019Shore CapitalDowngradeBuy ➝ HoldLow
2/22/2019UBS GroupDowngradeBuy ➝ NeutralLow
1/14/2019Exane BNP ParibasDowngradeOutperform ➝ NeutralMedium
1/14/2019BNP ParibasDowngradeOutperform ➝ NeutralMedium
12/14/2018Morgan StanleyInitiated CoverageUnderweightLow
12/13/2018SunTrust BanksInitiated CoverageHold$38.00Low
12/11/2018Jefferies Financial GroupReiterated RatingBuy ➝ Buy$45.00Low
12/6/2018BarclaysReiterated RatingOverweight ➝ Equal WeightMedium
12/4/2018CfraReiterated RatingHoldMedium
12/4/2018BarclaysDowngradeOverweight ➝ Equal Weight$36.95Low
12/3/2018JPMorgan Chase & Co.Reiterated RatingNeutralLow
10/29/2018JPMorgan Chase & Co.Reiterated RatingNeutralLow
10/23/2018Wolfe ResearchInitiated CoverageMarket PerformMedium
10/10/2018The Goldman Sachs GroupReiterated RatingBuyLow
10/8/2018GuggenheimInitiated CoverageNeutral ➝ NeutralLow
9/25/2018JPMorgan Chase & Co.Reiterated RatingNeutralLow
8/30/2018Liberum CapitalDowngradeBuy ➝ HoldLow
8/20/2018ArgusBoost Price TargetBuy ➝ Buy$45.00 ➝ $47.00Low
8/1/2018Deutsche Bank AktiengesellschaftReiterated RatingNeutralLow
7/27/2018Shore CapitalUpgradeHold ➝ BuyLow
7/25/2018Bank of AmericaSet Price TargetHold$40.00Medium
7/20/2018JPMorgan Chase & Co.Reiterated RatingNeutralHigh
6/14/2018DZ BankReiterated RatingBuyLow
4/9/2018Deutsche Bank AktiengesellschaftReiterated RatingNeutralLow
4/4/2018BNP ParibasUpgradeNeutral ➝ OutperformMedium
3/28/2018Deutsche Bank AktiengesellschaftReiterated RatingNeutralMedium
3/22/2018Morgan StanleyUpgradeUnderweight ➝ Equal WeightMedium
2/15/2018CowenReiterated RatingHold$40.00Low
2/9/2018Kepler Capital MarketsUpgradeReduce ➝ HoldLow
2/5/2018JPMorgan Chase & Co.Reiterated RatingNeutralHigh
1/29/2018JPMorgan Chase & Co.Reiterated RatingNeutralLow
1/16/2018BarclaysUpgradeEqual Weight ➝ OverweightLow
1/15/2018UBS GroupReiterated RatingBuyMedium
1/11/2018JPMorgan Chase & Co.Reiterated RatingNeutralLow
12/11/2017CowenSet Price TargetHold$38.00Low
11/30/2017ArgusLower Price TargetBuy$40.00Low
11/27/2017UBS GroupUpgradeNeutral ➝ Buy$35.04 ➝ $35.85Low
11/6/2017InvestecDowngradeBuy ➝ HoldN/A
10/26/2017Bank of AmericaDowngradeBuy ➝ NeutralN/A
10/24/2017JPMorgan Chase & Co.Reiterated RatingNeutralN/A
10/18/2017JPMorgan Chase & Co.Reiterated RatingNeutralN/A
9/21/2017JPMorgan Chase & Co.Reiterated RatingNeutralLow
9/14/2017JPMorgan Chase & Co.Reiterated RatingNeutralLow
9/8/2017Morgan StanleyDowngradeEqual Weight ➝ UnderweightLow
8/31/2017ArgusReiterated RatingBuy$50.00Low
(Data available from 8/9/2017 forward)

News Sentiment Rating

0.22 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 7 very positive mentions
  • 11 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
  • 5 very positive mentions
  • 10 positive mentions
  • 3 negative mentions
  • 2 very negative mentions
  • 1 very positive mentions
  • 17 positive mentions
  • 5 negative mentions
  • 1 very negative mentions
  • 0 very positive mentions
  • 18 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
  • 8 very positive mentions
  • 27 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
  • 6 very positive mentions
  • 9 positive mentions
  • 2 negative mentions
  • 2 very negative mentions
  • 9 very positive mentions
  • 27 positive mentions
  • 6 negative mentions
  • 1 very negative mentions
  • 5 very positive mentions
  • 29 positive mentions
  • 7 negative mentions
  • 2 very negative mentions

Current Sentiment

  • 5 very positive mentions
  • 29 positive mentions
  • 7 negative mentions
  • 2 very negative mentions

Recent Stories by Sentiment

GSK logo
GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, HIV, immuno-inflammation, oncology, anti-viral, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterial, and dermatology. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories. The company offers its consumer healthcare products in the form of nasal sprays, tablets, syrups, lozenges, gum and trans-dermal patches, caplets, infant syrup drops, liquid filled suspension, wipes, gels, effervescents, toothpastes, toothbrushes, mouthwashes, denture adhesives and cleansers, topical creams and non-medicated patches, lip balm, gummies, and soft chews. It has collaboration agreements with 23andMe; Lyell Immunopharma, Inc.; Novartis; Sanofi SA; Surface Oncology; Progentec Diagnostics, Inc.; Alector, Inc.; and CureVac AG., as well as strategic partnership with IDEAYA Biosciences, Inc. and Vir Biotechnology, Inc. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.
Read More

Today's Range

Now: $40.17
Low: $40.00
High: $40.33

50 Day Range

MA: $42.50
Low: $40.22
High: $44.42

52 Week Range

Now: $40.17
Low: $37.80
High: $46.97


32,086 shs

Average Volume

4,763,844 shs

Market Capitalization

$81.69 billion

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of GSK?

The following Wall Street sell-side analysts have issued reports on GSK in the last twelve months: AlphaValue, Barclays PLC, Berenberg Bank, Citigroup Inc., Credit Suisse Group AG, DZ Bank AG, JPMorgan Chase & Co., Morgan Stanley, Stifel Nicolaus, StockNews.com, TheStreet, and UBS Group AG.
View the latest analyst ratings for GSK.

What is the current price target for GSK?

4 Wall Street analysts have set twelve-month price targets for GSK in the last year. Their average twelve-month price target is $1,787.50, suggesting a possible upside of 4,334.4%. JPMorgan Chase & Co. has the highest price target set, predicting GSK will reach $1,900.00 in the next twelve months. Credit Suisse Group AG has the lowest price target set, forecasting a price of $1,600.00 for GSK in the next year.
View the latest price targets for GSK.

What is the current consensus analyst rating for GSK?

GSK currently has 1 sell rating, 7 hold ratings and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in GSK, but not buy more shares or sell existing shares.
View the latest ratings for GSK.

What other companies compete with GSK?

How do I contact GSK's investor relations team?

GSK's physical mailing address is 980 GREAT WEST ROAD, BRENTFORD X0, TW8 9GS. The pharmaceutical company's listed phone number is 442080475000 and its investor relations email address is [email protected] The official website for GSK is www.gsk.com. Learn More about contacing GSK investor relations.